Binding of an arm repeat protein to the kinase domain of the S-locus receptor kinase

Screening of a yeast two-hybrid library for proteins that interact with the kinase domain of an S-locus receptor kinase (SRK) resulted in the isolation of a plant protein called ARC1 (Arm Repeat Containing). This interaction was mediated by the C-terminal region of ARC1 in which five arm repeat units were identified. Using the yeast two-hybrid system and in vitro binding assays, ARC1 was found to interact specifically with the kinase domains from SRK-910 and SRK-A14 but failed to interact with kinase domains from two different Arabidopsis receptor-like kinases. In addition, treatment with a protein phosphatase or the use of a kinase-inactive mutant reduced or abolished the binding of ARC1 to the SRK-910 kinase domain, indicating that the interaction was phosphorylation dependent. Lastly, RNA blot analysis revealed that the expression of ARC1 is restricted to the stigma, the site of the self-incompatibility response.     

Patterns of growth and perception: the site, the city and the wild

The natural or biological world often provides models of the simplicity, elegance and complex interactivity that we seek to impart to our technologies, buildings and artworks. Within discussions of form, materials or functionality, we look to the world of insects, animals, plants and even our own bodies for solutions and innovation. Though we may work with the organisms themselves, the first step usually involves a rupture of context, a mutation of interdependent being into a discrete object, a model for the extraction of desired characteristics. The reality of embedded wild growth, with its complexity and interrelation, has often been described in terms of infestation or of ‘nature taking over,’ a challenge to our dominance of the world. However, a closer study of this interpenetration of uncontrolled nature within spaces around us reveals our immediate surroundings to be both wilder and more alive than we often presume them to be.     

OXIDATION OF HYDROCARBONS BY HEMIN1

A model system for cytochrome P-450 comprised of hemin, thiosalicylic acid, and solvent (acetone and water), oxidized cyclohemne and n-hexane at pH 2.7. Oxidation of cyclohexane yielded more cyclohexanol than cyclohexanone under mild reaction conditions, whereas the oxidation of n-hexane generated more 3- and 2-hexanones than 3- and 2-hemnols. Oxygen was a limiting factor in the reaction, and increased oxygen pressures increased the ratio of cyclohexanone to cyclohexanol formed. Lag time for product formation decreased in a linear fashion with an increase in temperature. In addition, cyclohexanone decreased relative to cyclohexanol as the temperature was increased. Antioxidants increased the lag time for product formation, but had little effect on the final quantity or ratios of the oxidative products generated. 1,3 Diphenylisobenzafiran had no effect on the lag time, whereas Tiron and catechol increased the lag time. In contrast to aliphatic thiols, aromatic thiols were capable of driving the oxidative reaction. The model hemin system was approximately 6% as active as natural cytochrome P-450. Hemin immobilized on glass beads effectively catalyzed the oxidation of cyclohexane.     

How the Wastewater Discharge Fee Might Become a Tool of River-Basin Management

The Federal German Water Law of 1976 postulated for the first time that a licence for the discharge of wastewater into public watercourses might only be granted when the wastewater, prior to discharge, is treated according to laid-down standards. In 1976 it was also decided that for the residual pollution load in sewage-treatment plant effluents a pollution fee has to be paid.
At present three pollution units have to be paid per capita and annually for untreated domestic wastewater. One pollution unit is assessed at 17/annum, but the price will be increased to 30/annum in future.
Since the pollution units encompass COD, nitrogen, phosphorus, heavy metals, and chlorinated hydrocarbon compounds, the pollution unit is a good tool to compare the effectiveness of treatment. For different drainage systems the residual pollution units (per litre and second) can also be calculated for low-flow conditions.     

Management of chylothorax

BACKGROUND: Chylothorax is a rare primary or secondary condition the optimum management of which remains uncertain. METHODS: Twenty cases of chylothorax, including ten of primary chylothorax and ten secondary to either malignancy, subclavian vein thrombosis or lymphangioma treated between 1956 and 1986 have been reviewed. RESULTS: Open pleurectomy was the most successful treatment in preventing reaccumulation of the effusion. Three patients had thoracic duct-azygous vein anastomoses, but all anastomoses were probably occluded within a year of surgery. Three patients have been lost to follow-up and five died within 2 years of their treatment, but 12 patients were alive and free from an effusion 3-22 years after treatment. CONCLUSION: Patients with chylothorax should undergo lymphangiography to identify the cause and site of the lymphatic abnormality. Conservative treatment is successful in some patients but should be abandoned if the fluid loss exceeds 1.5 l/day for more than 5-7 days in an adult or more than 100 ml/day in a child. Parietal pleurectomy is the most successful treatment when no distinct chylous leak can be identified. Less commonly, an isolated chylous leak either in the chest or in the abdomen may be identified and this should be treated by direct ligation.     

Design, construction and evaluation of systems to predict risk in obstetrics

We present a systematic, practical approach to developing risk prediction systems, suitable for use with large databases of medical information. An important part of this approach is a novel feature selection algorithm which uses the area under the receiver operating characteristic (ROC) curve to measure the expected discriminative power of different sets of predictor variables. We describe this algorithm and use it to select variables to predict risk of a specific adverse pregnancy outcome: failure to progress in labour. Neural network, logistic regression and hierarchical Bayesian risk prediction models are constructed, all of which achieve close to the limit of performance attainable on this prediction task. We show that better prediction performance requires more discriminative clinical information rather than improved modelling techniques. It is also shown that better diagnostic criteria in clinical records would greatly assist the development of systems to predict risk in pregnancy.     

Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition

To determine whether a functional type II receptor of transforming growth factor beta (TGF-beta) is required to mediate the growth inhibitory effect of TGF-beta on the skin in vivo, we have generated transgenic mice that overexpress a dominant negative-type II TGF-beta receptor (delta beta RII) in the epidermis. The delta beta RII mice exhibited a thickened and wrinkled skin, and histologically the epidermis was markedly hyperplastic and hyperkeratotic. In vivo labeling with BrdUrd showed a 2.5-fold increase in the labeling index over controls, with labeled nuclei occurring in both basal and suprabasal cells of transgenic epidermis. In heterozygotes, this skin phenotype gradually diminished, and by 10-14 days after birth the transgenic mice were indistinguishable from their normal siblings. However, when F1 mice were mated to homozygosity, perinatal lethality occurred due to the severe hyperkeratotic phenotype, which restricted movement. Cultured primary keratinocytes from delta beta RII mice also exhibited an increased rate of growth in comparison with nontransgenic controls, and were resistant to TGF-beta-induced growth inhibition. These data document the role of the type II TGF-beta receptor in mediating TGF-beta-induced growth inhibition of the epidermis in vivo and in maintenance of epidermal homeostasis.     

The entry of antiviral and antiretroviral drugs into the central nervous system

The ability of antiviral and antiretroviral drugs to enter the brain is a critical issue in the treatment of many viral brain diseases, including HIV-related neurologic disease. Much of the literature concerning nucleoside analog entry into the nervous system focuses on drug levels in the cerebrospinal fluid (CSF), equating these with drug levels in the brain extracellular fluid (ECF) as though the two compartments intermix freely. We review the anatomic and physiologic aspects of drug entry into CSF and into brain ECF, as well as the exchange processes between these two compartments. In most instances drug concentrations in the CSF and ECF compartments bear little relationship to one another and using CSF concentrations to extrapolate brain ECF concentrations may significantly overestimate the latter. Accepted terminology and methodology for making measurements of blood-brain barrier function are discussed. Studies of brain uptake that express results as brain:plasma ratios, or that have used microdialysis, may overestimate the amount of drug reaching the brain. Using published data, we present an estimate of the time course of Zidovudine (AZT) concentrations in brain ECF and show that brain concentrations of AZT will likely be below that necessary to inhibit HIV-1 replication when AZT is administered systemically. Antiviral nucleosides and oligonucleotides appear to have limited entry into the brain when given systemically, which may hinder therapy of viral brain diseases, while some of the protease inhibitors may enter the brain more readily. Alternative methods for increasing antiviral and antiretroviral drug delivery to brain are discussed.